269 related articles for article (PubMed ID: 11911426)
1. Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma.
Cohen Y; Polliack A; Zelig O; Goldfarb A
Leuk Lymphoma; 2001; 42(6):1405-8. PubMed ID: 11911426
[TBL] [Abstract][Full Text] [Related]
2. Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia.
Fabbri A; Gozzetti A; Lazzi S; Lenoci M; D'Amuri A; Leoncini L; Lauria F
Clin Lymphoma Myeloma; 2006 May; 6(6):496-9. PubMed ID: 16796783
[TBL] [Abstract][Full Text] [Related]
3. [Efficacity of rituximab in hemolytic anemia with cold autoantibodies case].
Sekkach Y; Hammi S; Elqatni M; Fatihi J; Elomri N; Mekouar F; Badaoui M; Jira M; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
Ann Pharm Fr; 2011 Jul; 69(4):205-8. PubMed ID: 21840439
[TBL] [Abstract][Full Text] [Related]
4. Remission of severe cold agglutinin disease after Rituximab therapy.
Layios N; Van Den Neste E; Jost E; Deneys V; Scheiff JM; Ferrant A
Leukemia; 2001 Jan; 15(1):187-8. PubMed ID: 11243390
[No Abstract] [Full Text] [Related]
5. Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.
Tanaka H; Hashimoto S; Sugita Y; Sakai S; Takeda Y; Abe D; Takagi T; Nakaseko C
Int J Hematol; 2012 Oct; 96(4):501-5. PubMed ID: 22878940
[TBL] [Abstract][Full Text] [Related]
6. [Rituximab in cold agglutinin disease].
Camou F; Viallard JF; Pellegrin JL
Rev Med Interne; 2003 Aug; 24(8):501-4. PubMed ID: 12888170
[TBL] [Abstract][Full Text] [Related]
7. [Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature].
Adam Z; Pejchalová A; Chlupová G; Ríhová L; Pour L; Krejčí M; Cervinek L; Král Z; Mayer J
Vnitr Lek; 2013 Sep; 59(9):828-40. PubMed ID: 24073955
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.
Zaja F; Vianelli N; Sperotto A; Patriarca F; Tani M; Marin L; Tiribelli M; Candoni A; Baccarani M; Fanin R
Leuk Lymphoma; 2003 Nov; 44(11):1951-5. PubMed ID: 14738149
[TBL] [Abstract][Full Text] [Related]
9. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy.
Mori A; Tamaru J; Sumi H; Kondo H
Eur J Haematol; 2002 Apr; 68(4):243-6. PubMed ID: 12071942
[TBL] [Abstract][Full Text] [Related]
11. Rituxan in the treatment of cold agglutinin disease.
Lee EJ; Kueck B
Blood; 1998 Nov; 92(9):3490-1. PubMed ID: 9787200
[No Abstract] [Full Text] [Related]
12. Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease.
Vassou A; Alymara V; Chaidos A; Bourantas KL
Int J Hematol; 2005 Jun; 81(5):421-3. PubMed ID: 16158824
[TBL] [Abstract][Full Text] [Related]
13. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.
Jourdan E; Topart D; Richard B; Jourdan J; Sotto A
Leuk Lymphoma; 2003 May; 44(5):889-90. PubMed ID: 12802933
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients.
Schöllkopf C; Kjeldsen L; Bjerrum OW; Mourits-Andersen HT; Nielsen JL; Christensen BE; Jensen BA; Pedersen BB; Taaning EB; Klausen TW; Birgens H
Leuk Lymphoma; 2006 Feb; 47(2):253-60. PubMed ID: 16321854
[TBL] [Abstract][Full Text] [Related]
15. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab.
Ramanathan S; Koutts J; Hertzberg MS
Am J Hematol; 2005 Feb; 78(2):123-6. PubMed ID: 15682420
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC
Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
18. Severe refractory autoimmune hemolytic anemia with five-year complete hematologic response to third course of treatment with rituximab: a case report.
Abadie K; Hege KM
J Med Case Rep; 2014 Jun; 8():175. PubMed ID: 24889270
[TBL] [Abstract][Full Text] [Related]
19. [Alleviated anemia by bendamustine in cold agglutinin disease associated with small lymphocytic lymphoma].
Kuno M; Inoue A; Aimoto M; Nakao T; Kameda K; Yoshida M; Kanashima H; Hirai M; Yamane T
Rinsho Ketsueki; 2015 Feb; 56(2):204-9. PubMed ID: 25765801
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma.
Bauduer F
Br J Haematol; 2001 Mar; 112(4):1085-6. PubMed ID: 11324638
[No Abstract] [Full Text] [Related]
[Next] [New Search]
